[
  {
    "ts": null,
    "headline": "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
    "summary": "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units (\"RSUs\"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.",
    "url": "https://finnhub.io/api/news?id=fc8112b9be60971bdbc82af207397958b6ed54b57f394d30a3541166f364e097",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764624600,
      "headline": "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
      "id": 137659942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,200 restricted stock units (\"RSUs\"), each representing the right to receive one share of its common stock upon vesting, to 15 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.",
      "url": "https://finnhub.io/api/news?id=fc8112b9be60971bdbc82af207397958b6ed54b57f394d30a3541166f364e097"
    }
  },
  {
    "ts": null,
    "headline": "Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors",
    "summary": "PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),",
    "url": "https://finnhub.io/api/news?id=cecceb4984c37d5b705aee39fafd6f40a5ed9494553aec1066b902ead6f9ced2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764597600,
      "headline": "Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors",
      "id": 137659254,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),",
      "url": "https://finnhub.io/api/news?id=cecceb4984c37d5b705aee39fafd6f40a5ed9494553aec1066b902ead6f9ced2"
    }
  }
]